Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GLSI
GLSI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GLSI News
Greenwich LifeSciences Receives Nasdaq Notification Regarding 10-K Filing
Apr 22 2026
seekingalpha
Greenwich LifeSciences Expands Vaccine Trial to Broader Patient Population
Apr 20 2026
stocktwits
Greenwich LifeSciences Presents Significant Data from GLSI-100 Phase III Trial
Apr 20 2026
NASDAQ.COM
Greenwich LifeSciences Updates Financing Strategy Amid Phase III Trial Progress
Apr 14 2026
Newsfilter
Greenwich LifeSciences Updates Patent Claims for GLSI-100
Apr 07 2026
Newsfilter
Greenwich LifeSciences Reports Promising Phase 3 Trial Data for GLSI-100
Mar 17 2026
NASDAQ.COM
Greenwich LifeSciences Shares Surge 13% on Positive Immunotherapy Trial Results
Mar 17 2026
stocktwits
Greenwich LifeSciences Updates on FLAMINGO-01 Trial Progress
Mar 17 2026
Yahoo Finance
Greenwich LifeSciences Accelerates Clinical Trial Screening Rate
Mar 03 2026
NASDAQ.COM
Greenwich LifeSciences Updates on Clinical Trial Progress
Mar 03 2026
Newsfilter
Greenwich LifeSciences Announces AACR Abstracts for FLAMINGO-01
Feb 24 2026
Newsfilter
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
PRnewswire
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
Newsfilter
Sarepta Therapeutics Reports Significant Three-Year Study Results
Jan 26 2026
Benzinga
Greenwich LifeSciences (GLSI) Gains FDA Approval for GP2, Stock Rises 27.8%
Jan 22 2026
Benzinga
Greenwich LifeSciences (GLSI) Receives FDA Approval for First Commercial GP2 Lot in Phase 3 Trial
Jan 22 2026
NASDAQ.COM
Show More News
